Overview

Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)

Status:
NOT_YET_RECRUITING

Trial end date:
2028-03-28

Target enrollment:

Participant gender:

Summary

This study is a phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose range finding study designed to explore the efficacy, safety, and tolerability of 2 active treatment regimens of CSL787 (nebulized immunoglobulin G \[IgG\]) compared with placebo over 6 to 12 months to prolong the time to first (TTF) exacerbation as a primary endpoint. The primary aim of the study is to characterize the overall effect of CSL787 as well as the dose response of 2 active treatment regimens of inhaled CSL787 administered to participants with NCFB over a period of greater than or equal to (\>=) 6 months but not exceeding 12 months toward prolonging the TTF exacerbation.

Phase:

PHASE2

Details

Lead Sponsor:

CSL Behring

Treatments:

Nebulizers and Vaporizers